Recurrent hyperlipidemic pancreatitis
Conditions
Interventions
Experimental group:Intestinal flora transplantation was given, and the patient was given 1 package of polyethylene glycol 4000 powder for intestinal flora transplantation, laxative intestinal preparat
Control group:No
Sponsors
The First Affiliated Hospital of Chengdu Medical College
Eligibility
Sex/Gender
All
Age
19 Years to 65 Years
Inclusion criteria
Inclusion criteria: Meet patients with acute pancreatitis with recurrent hyperlipidemia:AP Diagnosis According to the Classification of Acute Pancreatitis-2012: International Consensus Revision of the Atlanta Classification and Definition, the diagnostic criteria for acute pancreatitis are met by at least two of the following: (1) persistent abdominal pain in the upper abdomen; (2) serum amylase and/or lipase exceeding three times the upper limit of the normal range; and (3) abdominal imaging findings that support imaging changes in acute pancreatitis ( enhanced CT, MRI, abdominal ultrasound, EUS, etc.). Severity evaluated according to the Classification of Acute Pancreatitis-2012: International Consensus Revised Atlanta Classification and Definitions.Diagnostic criteria for HTGP: (1) Firstly, meet the diagnostic criteria for AP in the New Grading, Classification System for Acute Pancreatitis, Atlanta, GA, 2012. (2) Secondly, combined with hypertriglyceridemia (HTG) [serum TG level >= 1,000 mg/dl (11.30 mmol/L)], or serum TG level between 500 and 1,000 mg/dl (5.65 and 11.30 mmol/L) but with celiac disease. The diagnosis of HTG-AP was established if both (1) and (2) were met and other etiologies of AP such as bile duct disease, alcohol, trauma, and tumor were excluded.RAP was defined as >= 2 episodes of AP without permanent histologic changes such as pancreatic endo- and exocrine dysfunction, fibrosis, or calcification, and the interval between the 2 episodes was >= 3 months.
Exclusion criteria
Exclusion criteria: Females under the age of 18, pregnant or breastfeeding; Abdominal pain to >48 hours from the time of admission; Combined with liver cirrhosis, chronic renal failure, autoimmune diseases, hematologic diseases, malignant tumors, immunodeficiency syndromes and other diseases; Concomitant diabetic ketoacidosis on admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macrogenomic sequencing analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| metabolomics; | — |
Countries
China
Contacts
Public ContactXia Chen
Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College
Outcome results
None listed